Juvederm Voluma for Cheeks and Chin

Juvéderm Voluma XC is one of six hyaluronic acid fillers in Allergan's Juvéderm collection, which Allergan describes as covering cheeks, chin, temples, smile lines, lips, under-eyes and jawline, each product for its own labeled areas.

Hyaluronic acid is a sugar that the FDA says is naturally present in skin; the HA used in fillers comes from bacteria or rooster combs and is often chemically crosslinked so it lasts longer.

In the US, dermal fillers are regulated as medical devices that the FDA approves through premarket approval.

Voluma holds three approvals: on October 22, 2013, deep injection for cheek augmentation to correct age-related midface volume deficit in adults over the age of 21; on June 12, 2020, chin augmentation to improve the chin profile; and on October 6, 2023, injection to augment the temple region for moderate to severe temple hollowing, also in adults over 21.

The FDA says fillers are approved for adults over 21 for specific uses, with each product's label setting the exact age.

Every other use — the lips, the under-eyes, the nose, the jawline — is not on Voluma's current US label, and using a filler outside its approved indications is called off-label.

Allergan's important safety information adds that Voluma's safety was not studied in patients under 35 or over 65 for cheeks, under 22 or over 80 for chin, and under 32 or over 82 for temples.

Our Juvederm guide covers the rest of the collection, product by product.

The cheek approval is Voluma's oldest, from October 22, 2013, and its wording is specific: deep (subcutaneous and/or supraperiosteal) injection — under the skin and/or on the surface of the cheekbone — for cheek augmentation to correct age-related volume deficit in the midface, in adults over 21.

Allergan says Juvéderm results are visible immediately after treatment and that the products are injected with a needle or a cannula.

For duration, Allergan's stated maximum for the cheeks is up to 2 years with optimal treatment — the maker's own claim about a maximum, not an average and not a promise for any one person.

Side effects in the Voluma XC cheek study, as Allergan reports them, were moderate and generally lasted 2 to 4 weeks; the most common were tenderness, swelling, firmness, lumps/bumps, bruising, pain, redness, discoloration and itching.

Allergan also notes that Voluma's safety was not studied in patients under 35 or over 65 for cheek augmentation.

For the cheek area as a whole — the other approved products and what a session involves — see our cheek filler overview.

On June 12, 2020, Voluma was approved for chin augmentation to improve the chin profile, which made the chin its second labeled area.

Allergan's stated maximum duration for the chin is up to 1 year with optimal treatment — shorter than the cheek figure, and again the maker's own claim.

The indication covers the chin profile itself; any other use in the area is not on Voluma's label.

Allergan notes that Voluma's safety was not studied in patients under 22 or over 80 for chin augmentation.

For the chin area as a whole — including the other products approved there — see our chin filler guide.

Allergan's stated maximums, each hedged with the maker's phrase "with optimal treatment," are: cheeks up to 2 years, chin up to 1 year and temples up to 13 months.

These are the manufacturer's own maximum-duration claims, published on its consumer site.

They are not averages, and they are not a prediction for any individual.

The FDA's benchmark is broader: its general estimate for hyaluronic acid fillers as a material is that effects last approximately 6 to 12 months.

The two sets of numbers are not like-for-like — the FDA figure is a class-level estimate for HA fillers, while Allergan's are per-product maximums for Voluma in each labeled area — so we give you both rather than picking one.

None of these figures tells you what your results will do.

That is a question for the licensed provider who examines and treats you, and it is a fair question to ask before you book.

We could not confirm a Voluma-specific national price, so we won't invent one.

The closest confirmed figures are broader than Voluma.

Allergan's consumer site says Juvéderm treatment "can range from $600–$1,400", varying by product and provider — a range for the whole Juvéderm line, attributed to the maker.

The American Society of Plastic Surgeons (ASPS) lists an average cost of $715 for hyaluronic acid fillers.

That number is the average fee reported by ASPS member plastic surgeons — not med spa prices — and the ASPS page does not state the data year.

The two figures come from different sources; neither is a quote for your treatment.

What moves the price?

ASPS says dermal filler cost varies with the injector's expertise and qualifications, the type of procedure, the time and effort required and the geographic location of the office.

Health insurance does not cover dermal fillers.

Allergan's Allē rewards program gives 100 points = $10 toward qualifying treatments, including Juvéderm, per the program's terms.

For a real number, ask the providers you are considering what they charge for Voluma in the area you have in mind.